Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
5.63
-0.07 (-1.23%)
Jun 16, 2025, 10:08 AM - Market open
Company Description
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.
Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Tenax Therapeutics, Inc.
| Country | United States |
| Founded | 1967 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Christopher Giordano |
Contact Details
Address: 101 Glen Lennox Drive, Suite 300 Chapel Hill, North Carolina 27517 United States | |
| Phone | 919 855 2100 |
| Website | tenaxthera.com |
Stock Details
| Ticker Symbol | TENX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000034956 |
| CUSIP Number | 88032L209 |
| ISIN Number | US88032L6056 |
| Employer ID | 26-2593535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher T. Giordano | Chief Executive Officer, President and Director |
| Dr. Stuart Rich M.D. | Chief Medical Officer and Director |
| Thomas A. McGauley | Interim Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer |
| Doug Randall | Chief Business Officer |
| Dr. Douglas Hay Ph.D. | Executive Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 23, 2025 | EFFECT | Notice of Effectiveness |
| Apr 23, 2025 | 424B3 | Prospectus |